Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Non-Small-Cell Lung 10Uterine Cervical Neoplasms 8Squamous Cell Carcinoma of Head and Neck 6Stomach Neoplasms 5Triple Negative Breast Neoplasms 4Carcinoma, Renal Cell 4Advanced Solid Tumors 4Urinary Bladder Neoplasms 3Recurrence 3Pancreatic Neoplasms 3Melanoma 3Lung Neoplasms 3Solid Tumor 2Ovarian Neoplasms 2Neoplasms 2Neoplasm Metastasis 2Kidney Neoplasms 2Esophageal Neoplasms 2Colorectal Neoplasms 2Cholangiocarcinoma 2Breast Neoplasms 2Adenocarcinoma Of Esophagus 2Vulvar Neoplasms 1Vaginal Neoplasms 1Urothelial Bladder Carcinoma 1Thyroid Carcinoma, Anaplastic 1Thymoma 1Solid Tumors 1Solid Tumor, Unspecified, Adult 1Sarcoma 1

Interventions

Gemcitabine 6130-nm albumin-bound paclitaxel 4S 1 (combination) 2Radiosurgery 2Oxaliplatin 2Leucovorin 2Fluorouracil 2Electroporation 2zimberelimab 1surufatinib 1Tomography, X-Ray Computed 1Pancreatectomy 1Irinotecan 1Immunotherapy 1Heavy Ion Radiotherapy 1Endoscopy 1Drug Therapy 1Diagnostic Imaging 1Albumin-Bound Paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Locally Advanced Pancreatic Cancer × zimberelimab × Clear all
NCT06009029 2023-08-24

SBRT Combined With Zimberelimab (GLS-010) in Locally Advanced Pancreatic Cancer (SPARK-1 Study)

Peking University Third Hospital

Phase 2 Not yet recruiting
96 enrolled
Gastrointestinal

Locally Advanced Pancreatic Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡